Lacktman Quoted on Proposed Registration Process for Telemedicine Prescriptions
21 November 2019
Partner Nate Lacktman was quoted in an mHealth Intelligence article, “DEA Launches Registration Process for Prescriptions by Telemedicine,” about a long-awaited Justice Department proposal to create a special registration process that would allow health care providers to use telemedicine to prescribe controlled substances.
Lacktman, chair of the firm’s national Telemedicine & Digital Health Industry Team, has long called for such a move, the article pointed out, quoting from a blog post he co-authored in 2018 in which he said that existing regulations “fail to account for how legitimate telemedicine services are delivered today.”
Lacktman, chair of the firm’s national Telemedicine & Digital Health Industry Team, has long called for such a move, the article pointed out, quoting from a blog post he co-authored in 2018 in which he said that existing regulations “fail to account for how legitimate telemedicine services are delivered today.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”